OncTalk 2022
GRACE
Dual Immune Checkpoint Blockade With or Without Chemotherapy for mNSCLC
FEATURING
Chul Kim
- 288 views
- March 20, 2023
- 1
GRACE
Overcoming Resistance in ALK+ or KRAS+ NSCLC
FEATURING
Aakash Desai
- 115 views
- January 31, 2023
GRACE
NSCLC Trials for Patients With Actionable Mutations and the Importance of Quality of Life
- 152 views
- January 31, 2023
- 1
GRACE
The CheckMate 816 Trial: The Success of Neoadjuvant NSCLC Therapies
FEATURING
Julia Rotow
- 1,557 views
- January 26, 2023
- 6
GRACE
Studies in Oligometastatic NSCLC: Current Data and Definitions
FEATURING
Puneeth Iyengar
- 88 views
- January 19, 2023
GRACE
What Factors Determine a Successful Clinical Trial for NSCLC?
FEATURING
Puneeth Iyengar
- 37 views
- January 19, 2023
GRACE
Local Consolidative Therapy for Oligometastatic NSCLC: Ready for Primetime?
FEATURING
Puneeth Iyengar
- 162 views
- January 11, 2023
- 6
GRACE
Therapeutic Options in Driver-Mutation Positive mNSCLC Refractory to Frontline Small Molecular Inhibition
FEATURING
Aakash Desai
- 151 views
- January 11, 2023
- 1
GRACE
Frontline Treatment of Advanced NSCLC Without Actionable Driver Mutation
FEATURING
Chul Kim
- 210 views
- January 11, 2023
- 2